Biosimilar implementation
a progress report from FDA : hearing before the Subcommittee on Primary Health and Retirement Security of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fourteenth Congress, first session, on examining biosimilar implementation, focusing on a progress report from FDA, September 17, 2015
Biosimilar implementation
a progress report from Food and Drug Administration
United States
Congress.
Senate.
Committee on Health, Education, Labor, and Pensions.
Subcommittee on Primary Health and Retirement Security,
creator
text
bibliography
Legislative hearings.
Legislative hearings.
Rules.
dcu
2017
monographic
eng
iii, 40 pages : illustrations ; 24 cm.
Shipping list no.: 2018-0124-M.
CRDP Program record.
Includes bibliographical references.
Microfiche. [Washington, D.C.] : U.S. Government Printing Office, [2017] 1 microfiche : negative.
n-us---
United States.
Food and Drug Administration
Rules and practice
United States.
Food and Drug Administration.
Pharmaceutical biotechnology
United States
Management
Pharmaceutical biotechnology
Government policy
United States
Drug development
Government policy
United States
Drugs
Generic substitution
Government policy
United States
United States
KF26 .L2774 2015a
Y 4.L 11/4:S.HRG.114-700
Y 4.L 11/4:S.HRG.114-700
Biosimilar implementation
United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Subcommittee on Primary Health and Retirement Security.
(DLC) 2017434987
(OCoLC)1009576707
Biosimilar implementation
United States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Subcommittee on Primary Health and Retirement Security.
(OCoLC)1010499051
S. hrg. ; 114-700
United States.
Congress.
Senate.
PUCPR
190215
20190920130521.0
on1085907023
eng